Jafarzadeh A, Zarei S, Shokri F
Department of Immunology, School of Public Health, Medical Sciences/University of Tehran, Tehran 14155, Iran.
Vaccine. 2008 Jan 10;26(2):269-76. doi: 10.1016/j.vaccine.2007.10.044. Epub 2007 Nov 9.
A sizeable proportion (1-10%) of healthy adults and to lesser extent neonates vaccinated with triple 10 microg hepatitis B (HB) vaccine fail to mount a protective antibody response. Revaccination with the same vaccine dose has proved to be effective in a significant number of primary non-responders. The influence of revaccination with lower vaccine doses however has not been studied adequately in non-responder neonates. This study was conducted to evaluate the influence of supplementary vaccination with a single low and standard dose of a recombinant hepatitis B (HB) vaccine in healthy Iranian non-responder neonates to primary vaccination. Iranian neonates unable to respond to primary vaccination with 10, 5 or 2.5 microg doses of recombinant HB vaccine were revaccinated with a single additional dose of the same concentration. Serum anti-HBs antibody titer was measured by sandwich ELISA. Administration of a single additional dose induced seroprotection (anti-HBs> or =10IU/L) in 10/12 (83%), 10/12 (83%) and 21/24 (87.5%) of non-responder neonates in 10, 5 and 2.5 microg vaccine recipients with geometric mean titers (and 95% confidence limits) of 1358 (258-7142), 401 (79-2038) and 164 (62-433) IU/L, respectively. The log-transformed antibody titer obtained for the 10 microg dose recipients was significantly higher than that of the 2.5 microg dose vaccinees (p=0.028). No significant differences in anti-HBs titer were observed between other groups of vaccinees. However, the total seroprotection rates obtained after administration of four low doses of 2.5 and 5 microg were significantly higher than that obtained after administration of the classical three 10 microg doses (p=0.029 and p=0.006, respectively). The total seroprotection rates were similar between all groups of vaccines receiving four doses of 2.5, 5 and 10 microg vaccine doses. These results indicate that a significant proportion of non-responder neonates can be induced to develop a protective anti-HBs response following revaccination with a single low dose vaccine. Thus adaptation of four low dose (2.5 or 5 microg) vaccination is expected to induce higher seroprotection rate and lower or comparable anti-HBs antibody titer in healthy neonates.
相当比例(1%-10%)的健康成年人以及比例稍低的接种10微克重组乙肝疫苗的新生儿未能产生保护性抗体反应。对大量初次接种无反应者再次接种相同剂量疫苗已证明是有效的。然而,对于初次接种无反应的新生儿,较低剂量疫苗再次接种的影响尚未得到充分研究。本研究旨在评估单次低剂量和标准剂量重组乙肝疫苗补充接种对伊朗健康初次接种无反应新生儿的影响。对无法对10微克、5微克或2.5微克剂量重组乙肝疫苗初次接种产生反应的伊朗新生儿,再次接种单剂相同浓度的疫苗。采用夹心ELISA法检测血清抗-HBs抗体滴度。再次接种单剂疫苗后,10微克、5微克和2.5微克疫苗接种的初次接种无反应新生儿中,分别有10/12(83%)、10/12(83%)和21/24(87.5%)产生了血清保护作用(抗-HBs≥10IU/L),几何平均滴度(及95%置信区间)分别为1358(258-7142)、401(79-2038)和164(62-433)IU/L。10微克剂量接种者的对数转换抗体滴度显著高于2.5微克剂量接种者(p=0.028)。其他接种组之间抗-HBs滴度未观察到显著差异。然而,给予四剂2.5微克和5微克低剂量疫苗后的总血清保护率显著高于给予经典的三剂10微克剂量后的总血清保护率(分别为p=0.029和p=0.006)。接受四剂2.5微克、5微克和10微克疫苗剂量的所有疫苗接种组的总血清保护率相似。这些结果表明,相当比例的初次接种无反应新生儿在再次接种单剂低剂量疫苗后可诱导产生保护性抗-HBs反应。因此,预计采用四剂低剂量(2.5微克或5微克)接种方案可在健康新生儿中诱导更高的血清保护率以及更低或相当的抗-HBs抗体滴度。